Post-marketing safety signals of the ROCK2 inhibitor Belumosudil for chronic graft-versus-host disease: a real-world disproportionality analysis based on the FAERS database
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective To characterize the real-world post-marketing safety profile, evidence hierarchy, and demographic vulnerabilities of the selective ROCK2 inhibitor Belumosudil in chronic graft-versus-host disease (cGVHD) using FAERS. Methods Adverse event reports (Q3 2021–Q4 2025) were extracted from FAERS. To control indication confounding, primary disproportionality analysis was anchored to a disease-restricted cGVHD and hematopoietic stem cell transplantation background ( n = 921 , 529 ) using four consensus algorithms (ROR, PRR, BCPNN, MGPS) with False Discovery Rate (FDR) validation. Signals were filtered via a prespecified clinical protocol and stratified into a three-tier evidence framework. Subgroup vulnerabilities (prognostic mortality, age, sex) were evaluated using Fisher’s exact tests. Dual sensitivity analyses evaluated polypharmacy (monotherapy cohort with standardized mean difference [SMD] balance) and denominator stability (whole-database comparator). Results Among 1,797 primary suspect Belumosudil reports (6,056 adverse events), initial screening identified 61 consensus-positive Preferred Terms (PTs); 60 maintained FDR significance ( q < 0.05 ). After systematically excluding 16 confounded administrative and indication-synonymous terms, 45 core PTs were retained across three tiers (Tier 1 trial verification, n = 6 ; Tier 2 novel mechanistic signals, n = 6 ; Tier 3 clinical confounders, n = 33 ). Pharmacological toxicities clustered into three dimensions: musculoskeletal symptoms (muscle tightness, ROR = 10.25; skin swelling, ROR = 19.32), mucosal/viral infections (respiratory syncytial virus, ROR = 4.02; viral gastroenteritis, ROR = 4.81), and laboratory abnormalities (hepatic enzyme increased, ROR = 5.64; blood immunoglobulin G decreased, ROR = 5.75). Subgroup stratification identified distinct clinical vulnerabilities: fatal cases were enriched for obliterative bronchiolitis and muscle atrophy; elderly patients ( ≥ 65 years) exhibited predilection for joint stiffness and lip pain ( P < 0.05 ); and females displayed heightened susceptibility to transaminase elevation, skin atrophy, and oral mucosal blistering ( P < 0.05 ). Monotherapy sensitivity analysis ( N = 1 , 255 ; almost all baseline SMDs < 0.10 ) and whole-database comparison confirmed signal robustness. Conclusion Belumosudil’s real-world safety landscape is dominated by musculoskeletal tightness and edema, mucosal and viral infections, and transaminase/immunoglobulin fluctuations, without novel systemic organ toxicities. Findings underscore the necessity of tailored clinical surveillance: monitoring pulmonary decline in severe disease, joint stiffness in elderly recipients, and hepatic transaminases in females.
Source: Frontiers in Immunology
Language: English
Subfield: Toxicology
Domain: Life Sciences
Keywords: belumosudil, chronic graft-versus-host disease, ROCK2 inhibitor, post-marketing safety, adverse drug reactions, disproportionality analysis, hematopoietic stem cell transplantation, musculoskeletal toxicity, viral infection, elevated liver enzymes, elderly patients, sex differences, drug safety signals, FDA Adverse Event Reporting System, bronchiolitis obliterans
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226011982
